Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer’s treatment Leqembi, saw growth. But the biotech company’s…
